IL17A and Crohn disease: For example, the upregulation of WTAP was reversed in patients with psoriasis treated with anti-IL17A therapy and in patients with Crohn’s disease (CD) treated with anti-TNF therapy (GSE137218/16879; Supplemental Table 1); correspondingly, proinflammatory cytokine expression was also decreased in these patients after treatment (Figure 7, A and B).